Swiss Electrical Stock News

SWX:SFZN
SWX:SFZNLife Sciences

Siegfried Holding (SWX:SFZN) Stock Eyes Margin Gains Against Rich Valuation

Siegfried Holding stock went into this earnings print with a solid recent run, up about 13.5% over the past month and trading at CHF80.25, well above a discounted cash flow estimate of CHF59.01. The headline today is not a surprise beat or miss. It is a margin story. The company delivered a core EBITDA margin of 22.4% in the first half with management talking up further improvement above 23% for the full year. That mix of strong recent share gains, a richer price tag and quietly firming...
SWX:PSPN
SWX:PSPNReal Estate

PSP Swiss Property (SWX:PSPN) Could Be 82% Overvalued Following Strong Earnings

Why PSP Swiss Property’s latest earnings matter for investors PSP Swiss Property (SWX:PSPN) recently reported second quarter and half year 2026 earnings, highlighting higher net income and basic earnings per share while sales stayed broadly unchanged. This earnings profile is attracting fresh investor attention. See our latest analysis for PSP Swiss Property. Following the earnings announcement on 18 August 2026, PSP Swiss Property’s share price at CHF145.50 reflects a modest year to date...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is Novartis (SWX:NOVN) Fully Valued On Its 2026 ESC Congress Data Plans?

Why the 2026 ESC Congress Matters for Novartis Stock Novartis (SWX:NOVN) is back in focus after confirming plans to present data from 10 cardiovascular studies at the 2026 European Society of Cardiology Congress, including late breaking Leqvio and abelacimab results. See our latest analysis for Novartis. At a share price of CHF127.42, Novartis has shown firm momentum, with a 7 day share price return of 4.07%, a year to date share price return of 17.44%, and a 5 year total shareholder return...
SWX:BAER
SWX:BAERCapital Markets

Julius Bär Stock And Other European Safe Haven Financials In Focus

With investors questioning the reliability of US Treasuries and the dollar at the same time, attention is drifting toward markets that feel calmer and more predictable. That shift can create openings and risks in stocks linked to Swiss and other safe haven currencies, as clients reconsider where they hold their cash and portfolios. This article walks through three stocks exposed to that story and explains how the current backdrop could matter for each one. The sample of stocks covered below...
SWX:VZN
SWX:VZNCapital Markets

VZ Holding (SWX:VZN) Faces A 22% Above Fair Value Gap On Half Year Earnings

VZ Holding (SWX:VZN) is back in focus after reporting half year 2026 earnings on 14 August. Net income reached CHF 131.69 million, with basic earnings per share from continuing operations at CHF 3.34. See our latest analysis for VZ Holding. The earnings release appears to have supported momentum in VZ Holding’s share price, with a 30 day share price return of 8.68% and a 90 day share price return of 18.54%. Over a longer period, the 5 year total shareholder return of 120.71% contrasts with a...
SWX:TEMN
SWX:TEMNSoftware

Temenos (SWX:TEMN) Could Be 7% Undervalued As CHF 100 Million Buyback Starts

Temenos (SWX:TEMN) has announced a share repurchase program of up to CHF 100 million, authorized by its Board on 12 August 2026 and running until late February 2027, primarily for general corporate uses. See our latest analysis for Temenos. At a latest share price of CHF 74.40, Temenos has seen a 30 day share price return of 11.54% and a 1 year total shareholder return of 5.84%, while the 5 year total shareholder return remains down 43.41%. This suggests that recent momentum has improved from...
SWX:SDZ
SWX:SDZPharmaceuticals

Sandoz Group (SWX:SDZ) Looks Fully Valued After Henlius Biosimilar Deal

Sandoz Group (SWX:SDZ) is back in focus after the company agreed a collaboration with Shanghai Henlius Biotech to develop, manufacture and commercialise up to 10 biosimilars, with milestone payments up to US$322 million. See our latest analysis for Sandoz Group. The collaboration news arrives as Sandoz Group trades at CHF73.84, with a 30 day share price return of 15.45% and a year to date share price return of 29.05%. Over the past year, total shareholder return of 48.82% indicates that...
SWX:SENS
SWX:SENSElectronic

Sensirion Holding (SWX:SENS) Stock Grapples With FX Drag Despite Profit Jump

Sensirion Holding shares closed at CHF78.90 on Friday after a choppy week that left the stock slightly lower over seven days but modestly higher over the past month. The market reaction feels cautious. The headline from these H1 numbers is clear. Profitability in the sensor business is tightening under the microscope. Revenue for the first half came in at CHF179.0m while basic earnings per share reached CHF1.21. The key development is in the trailing picture. Net profit margin on the last...
SWX:SPSN
SWX:SPSNReal Estate

Swiss Prime Site (SWX:SPSN) Stock Premium Rests On Steady FFO Growth

Swiss Prime Site entered this earnings day with a mixed recent record. The stock is roughly flat over the past week, slightly down over one and three months, and valued on a rich P/E of 25.2x compared with lower sector averages. That sets a high bar for any real estate earnings print. The headline this time is about cash generation, not accounting profit. Funds From Operations, the key profit yardstick for property investors, reached about CHF 333m over the last twelve months and FFO per...
SWX:ZUGN
SWX:ZUGNReal Estate

Zug Estates Holding (SWX:ZUGN) Stock Premium Rests On One Off Gains

Zug Estates Holding went into this earnings day with a flat 7 day return and a share price around CHF 2,140 that had already cooled over the past month. The headline is not about rental income growth. It is about earnings quality. Reported net income sits at CHF 42.9m for the half year and the trailing figures still carry a CHF 26.8m one off gain that inflates profit margins. For you as an investor the key question now is how much of Zug Estates Holding’s rich P/E and premium to a discounted...
SWX:ROP
SWX:ROPPharmaceuticals

Roche (SWX:ROP) Stock Looks Undervalued As US Manufacturing Expansion Continues

Roche Holding stock has delivered a 60.7% return over the past three years, and the recent run raises the question of whether the current price still lines up with what the valuation checks suggest. Over the past 3 years, Roche Holding has returned 60.7%, which puts recent gains front and centre in any assessment of what investors are now paying for the stock. Large ongoing investments in U.S. manufacturing capacity and diagnostics partnerships can support future cash generation. However,...
SWX:SIGN
SWX:SIGNPackaging

Is SIG Group’s (SWX:SIGN) CEO Shift Quietly Redefining Its Aseptic Systems Investment Story?

SIG Group AG recently appointed Ann-Kristin Erkens as CEO, replacing Mikko Keto, as its transformation programme delivered higher adjusted EBIT margins and stronger free cash flow, while the company reiterated its 2026 outlook and focus on aseptic system solutions. The planned Capital Markets Day in October, where SIG will outline its updated strategy and mid-term targets, gives investors a clearer lens on how the transformation programme could influence future business priorities and...
SWX:DKSH
SWX:DKSHTrade Distributors

Why DKSH Holding (SWX:DKSH) Is Back In The Spotlight

DKSH Holding (SWX:DKSH) is back in focus after its Malaysian unit reported a 34.8% year-on-year jump in second quarter net profit, supported by higher revenue and unrealised foreign exchange gains. See our latest analysis for DKSH Holding. At a share price of CHF66.40, DKSH Holding has seen its 30 day share price return of 3.75% and year to date share price return of 13.31%. The 1 year total shareholder return is 19.71%, which suggests momentum has been building rather than fading...
SWX:SIKA
SWX:SIKAChemicals

Sika (SWX:SIKA) Could Be 6% Undervalued Following Hybrid Bond Issue And Stable Outlook

Sika (SWX:SIKA) has drawn fresh investor attention after issuing €1b in hybrid capital bonds split into two callable, subordinated tranches, while S&P shifted its issuer rating outlook on the company from Negative to Stable. See our latest analysis for Sika. For investors, the hybrid bond issuance and S&P outlook revision arrive as Sika’s share price shows renewed momentum, with a 30-day share price return of 17.92% and a 90-day gain of 25.14%, even though the 5-year total shareholder return...
SWX:CMHC
SWX:CMHCPharmaceuticals

Can Cosmo (SWX:CMHC) Re Rate As Hair Loss Data Raises Its Valuation Question?

Cosmo (SWX:CMHC) is back in focus after reporting 12 month Phase 3 data for its clascoterone 5% topical solution in male pattern hair loss, highlighting sustained efficacy and a safety profile comparable to vehicle. See our latest analysis for Cosmo. Despite the latest clascoterone update putting Cosmo back on investors’ radar, the stock has seen its share price fall 9.35% over the past month and 25.48% over the past quarter. At the same time, the 1 year total shareholder return of 7.43% and...
SWX:LAND
SWX:LANDElectronic

Is Landis+Gyr Group (SWX:LAND) A Bargain As It Expands Its Edge Ecosystem In Australia?

Landis+Gyr Group (SWX:LAND) recently expanded its Edge Application Ecosystem in Australia by adding Future Grid and Operational Technology Solutions as partners. For investors, this product move raises fresh questions about the stock’s positioning. See our latest analysis for Landis+Gyr Group. The Edge App Ecosystem update arrives after a mixed period for Landis+Gyr Group, with the share price at CHF46.85, a 30 day share price return of 6.96% but a year to date share price return that is down...
SWX:BSLN
SWX:BSLNBiotechs

Basilea Pharmaceutica (SWX:BSLN) Faces A 6% Above Fair Value View As Guidance Rises

Why Basilea Pharmaceutica stock is back in focus Basilea Pharmaceutica (SWX:BSLN) is drawing fresh attention after reporting CHF 119 million in first half 2026 revenue and CHF 27.95 million in net income, along with higher full year guidance for both total revenue and operating profit. See our latest analysis for Basilea Pharmaceutica. The latest earnings and raised guidance have been met with a sharp shift in sentiment. Basilea Pharmaceutica’s share price return is 23.1% over 90 days and the...
SWX:NREN
SWX:NRENReal Estate

Novavest Real Estate (SWX:NREN) Stock Faces One Off Profit Risk Behind 76% Margin

Novavest Real Estate stock closed at CHF39.00 on 20 August, roughly flat over the past week and down over the last quarter, even as the latest half year numbers landed with very strong profitability. The headline is the margin story. Net profit margin over the past twelve months reached 76%, supported by a CHF9.5m one off gain that lifts the optics of earnings far above the underlying trend. For you as an investor, this is a classic time horizon test. The short term readout looks impressive...
SWX:BCVN
SWX:BCVNBanks

Banque Cantonale Vaudoise (SWX:BCVN) Profitability Tightens As Capital Pressure Builds

Banque Cantonale Vaudoise came into this earnings day priced for perfection, trading on a rich 24.3x P/E and carrying a 3.62% dividend yield, yet the stock has drifted over the past month. The headline today is that profitability is being gently squeezed. Trailing net profit margin sits at 37.4%, slightly lower than the prior year, while risk weighted assets are climbing in step with mortgage and loan growth. For a bank already valued above Swiss and European peers, this margin pressure is...